Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

Executive Summary

Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.

You may also be interested in...



IPO Update: Biopharma Firms Give Thanks For Receptive US Investors

Six biopharma firms went public in the US in November during the three weeks leading up to Thanksgiving, raising $539.5m and counting. With 39 IPOs so far this year, 2017 has had nine more first-time offerings than 2016 with five more weeks to go.

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

Deals Shaping The Medical Industry, August 2021

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2021. Data provided by Biomedtracker.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel